Our CMO Dr. Monica Soni, and American Cancer Society's Chief Patient Officer Dr. Arif Kamal discuss current challenges and the future of effective palliative care.
Treating patients the same isn't always the path to improved outcomes, writes our associate chief medical officer.
Learn key strategies for health plans to reduce three types of inappropriate use in cardiovascular care.
Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.
Learn why underuse is a major problem and how we might tackle it
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.
Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.
The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.
New Century Health CMO, Dr. Andrew Hertler, shares his thoughts on the recent FDA meetings to review the merits of approved cancer drugs.
Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.
The therapeutic landscape in oncology is vast and everchanging, marked by a dramatic pace of innovation and new approvals. In this complicated specialty, how can payers and providers keep up?
In this podcast series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.
Our senior medical director speaks with Journal of Clinical Pathways about preventing inappropriate use in cardiology.
A new research effort aims to gauge whether certain groups of patients receive high-value therapies at lower rates than others.
NCH's approach to more appropriate use of myeloid growth factor provides a playbook for how to change prescribing patterns.
Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical oncology pathways.
Recent journal article details how NCH and Cancer Care Specialists of Illinois teamed up to slow growth in drug spend.
